Back to Treatments

Treatment

Liposomal Doxorubicin

2
Conditions
266
Trials
9,500
Participants
30%
Average Safety

Condition Evidence

Hepatoblastoma

6 trials · 2,000 participants

70% effectiveness · 28% safety

Ovarian cancer

260 trials · 7,500 participants

60% effectiveness · 32% safety
Liposomal Doxorubicin | DFDA